肺がんリキッドバイオプシーの世界市場：2024-2031年

肺がんリキッドバイオプシー市場は、予測期間（2024-2031年）に13.4%の大幅なCAGRで成長すると予測されます。肺がんリキッドバイオプシーは、体液中のバイオマーカーを用いた肺がんの検出とモニタリングのための診断技術です。低侵襲でリアルタイムであり、包括的な腫瘍プロファイリングを提供します。早期発見、治療効果、病勢進行の評価、治療抵抗性の同定に役立ちます。腫瘍学におけるこの進歩は、患者の転帰を改善します。

市場力学

技術の急速な進歩

次世代シークエンシング（NGS）やデジタルPCRなどの技術の進歩は、リキッドバイオプシーアッセイの感度、特異性、精度を高め、臨床現場での採用を促進しています。例えば、2022年12月、Agilent Technologies Inc.は、Agilent Resolution ctDx FIRSTについて、患者の進行非小細胞肺がんの同定に使用されるコンパニオン診断薬としてFDAの承認を取得しました。

医薬品開発と臨床試験

世界的に、リキッドバイオプシーは、患者の選択、治療効果のモニタリング、薬剤耐性の評価のためのバイオマーカーの同定を可能にすることにより、薬剤開発と臨床試験において重要な役割を果たしており、肺がんの標的療法と免疫療法の開発を加速させています。大学や研究機関における医薬品開発資金の増加は、世界市場の成長に大きく寄与しています。

市場セグメンテーション

世界の肺がんリキッドバイオプシー市場につき、以下のように詳細に分析しています。

• バイオマーカーに基づき、市場はCNA、CTC、エクソソーム/マイクロベシクル、循環タンパク質に区分されます。
• アプリケーションに基づくと、市場は治療法の選択、治療モニタリング、早期がんスクリーニング、再発モニタリングに区分されます。
• エンドユーザー別では、市場は病院・研究所、専門クリニック、学術・研究センターに区分されます。
• 製品別では、市場は機器、消耗品キット・試薬、ソフトウェア、サービスに区分されます。

治療法の選択が最大セグメントとして台頭すると予測される

個別化医療への傾向の高まり、標的治療の採用、組織生検の補完、非侵襲的でリアルタイムのモニタリング、臨床的エビデンス、急速な技術進歩などがこのセグメントの成長を支える主な要因です。リキッドバイオプシーは、各患者の腫瘍に関連する特定のバイオマーカーや遺伝子変異を同定することを可能にし、臨床医が患者固有の分子プロファイルに基づいて治療計画を調整することを可能にします。リキッドバイオプシーはまた、特に組織生検の結果が決定的でない、あるいは得られない場合において、治療法選択の精度を高める。肺がんにおける治療法選択のためのリキッドバイオプシーを支持する臨床エビデンスの増加と、次世代シークエンシングやデジタルPCRのような急速な技術進歩が、さらにリキッドバイオプシーの成長に寄与しています。

地域別展望

世界の肺がんリキッドバイオプシー市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋（インド、中国、日本、韓国、その他アジア太平洋地域）、世界のその他の地域（中東とアフリカ、中南米）を含む地域別にさらに細分化されます。

北米が主要市場シェアを占める

全地域の中で北米が大きなシェアを占めているのは、高度な医療インフラの存在、強力な研究開発エコシステム、規制の枠組み、早期臨床導入、患者数の多さ、疾病負担の大きさ、資本へのアクセス、バイオテクノロジーとヘルスケアイノベーションにおける世界のリーダーシップなどが背景にあります。米国とカナダは医療機器と診断検査に対する規制の枠組みが確立しており、リキッドバイオプシーアッセイの安全性、有効性、品質を保証しています。この地域の医療技術の早期導入の文化、高い医療費、高度診断に対する患者の需要、および支援的な償還環境は、臨床医がリキッドバイオプシーを標準的ながん治療のプロトコールに組み込むことを後押ししています。

世界の肺がんリキッドバイオプシー市場に参入している主要企業には、Eurofins Scientific社、MDxHealth社、CareDx社、Immucor社、Thermo Fisher Scientific社、Menarini Silicon Biosystems社、Qiagen社、Guardant Health社、Exact Sciences Corporation社などがあります。市場競争力を維持するために、提携、合併、買収などの戦略を適用して事業拡大や製品開発に注力する企業が増えています。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主要業界動向
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• CareDx, Inc.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Eurofins Scientific SE
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Qiagen NV
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• 肺がんリキッドバイオプシー治療の世界市場：バイオマーカー別
  • CNA
  • CTC
  • エクソソーム/マイクロベシクル
  • 循環タンパク質
• 肺がんリキッドバイオプシー治療の世界市場：用途別
  • 治療法の選択
  • 治療モニタリング
  • 早期がんスクリーニング
  • 再発モニタリング
• 肺がんリキッドバイオプシー治療の世界市場：エンドユーザー別
  • 病院・研究所
  • 専門クリニック
  • 学術・研究センター
• 肺がんリキッドバイオプシー治療の世界市場：製品別
  • 機器
  • 消耗品キット・試薬
  • ソフトウェア・サービス

第5章 地域別分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第6章 企業プロファイル

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Exact Sciences Corp.
• Guardant Health
• Immucor
• LungLife AI, Inc.
• MDxHealth
• Menarini Silicon Biosystems
• Myriad Genetics, Inc.
• Thermo Fisher Scientific Inc.

LIST OF TABLES

• 1. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Biomarker, 2023-2031 ($ Million)
• 2. Global Circulating Nucleic Acids Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
• 3. Global CTC Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
• 4. Global Exosomes/Microvesicles Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
• 5. Global Circulating Protein Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
• 6. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Application 2023-2031 ($ Million)
• 7. Global Lung Cancer Liquid Biopsy Treatment Therapy Session Market Research And Analysis By Region, 2023-2031 ($ Million)
• 8. Global Lung Cancer Liquid Biopsy Treatment for Treatment Monitoring Market Research And Analysis By Region, 2023-2031 ($ Million)
• 9. Global Lung Cancer Liquid Biopsy Treatment for Early Cancer Screening Market Research And Analysis By Region, 2023-2031 ($ Million)
• 10. Global Lung Cancer Liquid Biopsy Treatment For Recurrence Monitoring Market Research And Analysis By Region, 2023-2031 ($ Million)
• 11. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
• 12. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By end-User, 2023-2031 ($ Million)
• 13. Global Lung Cancer Liquid Biopsy Treatment for Hospitals And Laboratories Market Research And Analysis By Region, 2023-2031 ($ Million)
• 14. Global Lung Cancer Liquid Biopsy Treatment for Specialty Clinics Market Research And Analysis By Region, 2023-2031 ($ Million)
• 15. Global Lung Cancer Liquid Biopsy Treatment for Academics And Research Centers Market Research And Analysis By Region, 2023-2031 ($ Million)
• 16. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis Byproduct 2023-2031 ($ Million)
• 17. Global Lung Cancer Liquid Biopsy Treatment for Instruments Market Research And Analysis By Region, 2023-2031 ($ Million)
• 18. Global Lung Cancer Liquid Biopsy Treatment for Consumables Kits And Reagents Market Research And Analysis By Region, 2023-2031 ($ Million)
• 19. Global Lung Cancer Liquid Biopsy Treatment For Software And Services Market Research And Analysis By Region, 2023-2031 ($ Million)
• 20. Global Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Product 2023-2031 ($ Million)
• 21. North American Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Country, 2023-2031 ($ Million)
• 22. North American Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Biomarker, 2023-2031 ($ Million)
• 23. North American Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Application, 2023-2031 ($ Million)
• 24. North American Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Product, 2023-2031 ($ Million)
• 25. North American Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By End-User, 2023-2031 ($ Million)
• 26. European Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Country, 2023-2031 ($ Million)

27. European Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Biomarker, 2023-2031 ($ Million

• 28. European Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Application, 2023-2031 ($ Million)
• 29. European Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Product, 2023-2031'1 ($ Million)
• 30. European Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By End-User, 2023-2031 ($ Million)
• 31. Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Country, 2023-2031 ($ Million)
• 32. Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Biomarker, 2023-2031 ($ Million)
• 33. Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Application, 2023-2031 ($ Million)
• 34. Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Product, 2023-2031 ($ Million)
• 35. Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By End-User, 2023-2031 ($ Million)
• 36. Rest Of The World Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Region, 2023-2031 ($ Million)
• 37. Rest Of The World Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Biomarker, 2023-2031 ($ Million)
• 38. Rest Of The World Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Application, 2023-2031 ($ Million)
• 39. Rest Of The World Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By Product, 2023-2031 ($ Million)
• 40. Rest Of The World Lung Cancer Liquid Biopsy Treatment Market Research And Analysis By End-User, 2023-2031 ($ Million)

LIST OF FIGURES

• 1. Global Lung Cancer Liquid Biopsy Treatment Market Share By Biomarker, 2023 Vs 2031 (%)
• 2. Global Circulating Nucleic Acids Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
• 3. Global CTC Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
• 4. Global Exosomes/Microvesicles Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
• 5. Global Circulating Protein Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
• 6. Global Lung Cancer Liquid Biopsy Treatment Market Share By Application, 2023 Vs 2031 (%)
• 7. Global Therapy Session Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)

8. Global Treatment Monitoring Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)-

• 9. Global Early Cancer Screening Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
• 10. Global Recurrence Monitoring Applied Membranes Treatment Market Share By Region, 2023 Vs 2031 (%)
• 11. Global Lung Cancer Liquid Biopsy Treatment Market Share By End-User, 2023 Vs 2031 (%)
• 12. Global Lung Cancer Liquid Biopsy Treatment In Hospitals And Laboratories Market Share By Region, 2023 Vs 2031 (%)
• 13. Global Lung Cancer Liquid Biopsy Treatment In Specialty Clinics Market Share By Region, 2023 Vs 2031 (%)
• 14. Global Lung Cancer Liquid Biopsy Treatment In Academics And Research Centers Market Share By Region, 2023 Vs 2031 (%)
• 15. Global Lung Cancer Liquid Biopsy Treatment Market Share By Product, 2023 Vs 2031 (%)
• 16. Global Lung Cancer Liquid Biopsy Treatment Instruments Market Share By Region, 2023 Vs 2031 (%)
• 17. Global Lung Cancer Liquid Biopsy Treatment Consumables Kits And Reagents Market Share By Region, 2023 Vs 2031 (%)
• 18. Global Lung Cancer Liquid Biopsy Treatment Software And Services Market Share By Region, 2023 Vs 2031 (%)
• 19. Global Lung Cancer Liquid Biopsy Treatment Market Share By Region, 2023 Vs 2031 (%)
• 20. Us Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 21. Canada Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 22. UK Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 23. France Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 24. Germany Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 25. Italy Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 26. Spain Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 27. Rest Of Europe Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 28. India Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 29. China Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 30. Japan Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 31. South Korea Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 32. Rest Of Asia-Pacific Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 33. Latin America Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)
• 34. Middle East And Africa Lung Cancer Liquid Biopsy Treatment Market Size, 2023-2031 ($ Million)

Global Lung Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report by Biomarker (Circulating Nucleic Acids, CTC, Exosomes/Microvesicles, Circulating Proteins), by Application (Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring), by End-User (Hospitals and Laboratories, Specialty Clinics, Academic and Research Centers), by Product (Instruments, Consumables Kits and Reagents, Software and Services) Forecast Period (2024-2031)

The lung cancer liquid biopsy market is anticipated to grow at a significant CAGR of 13.4% during the forecast period (2024-2031). Lung cancer liquid biopsy is a diagnostic technique for lung cancer detection and monitoring, using biomarkers in bodily fluids. It is minimally invasive, real-time, and provides comprehensive tumor profiling. It aids in early detection, treatment response, disease progression assessment, and therapy resistance identification. This advancement in oncology improves patient outcomes.

Market Dynamics

Rapid Advancements in Technology

Ongoing advancements in technology, such as next-generation sequencing (NGS) and digital PCR, are enhancing the sensitivity, specificity, and accuracy of liquid biopsy assays, driving adoption in clinical practice. For instance, in December 2022, Agilent Technologies Inc. received FDA approval for Agilent Resolution ctDx FIRST as a companion diagnostic used to identify advanced non-small lung cancer in patients.

Drug Development and Clinical Trials

Globally, liquid biopsy is playing a crucial role in drug development and clinical trials by enabling the identification of biomarkers for patient selection, monitoring treatment response, and assessing drug resistance, thereby accelerating the development of targeted therapies and immunotherapies for lung cancer. The increasing funding for drug development in universities and research organizations is making a significant contribution to the growth of the global market.

Market Segmentation

Our in-depth analysis of the global lung cancer liquid biopsy market includes the following segments by type, product, and technology,

• Based on biomarkers, the market is segmented into circulating nucleic acids, CTC, exosomes/microvesicles, circulating proteins
• Based on application, the market is segmented into therapy selection, treatment monitoring, early cancer screening, recurrence monitoring
• Based on end-user, the market is segmented into hospitals and laboratories, specialty clinics, academic and research centers
• Based on product, the market is segmented into instruments, consumables kits and reagents, software and services

Therapy Selection is Projected to Emerge as the Largest Segment

The primary factors supporting the segment's growth due to the growing trend towards personalized medicine, targeted therapy adoption, complementary to tissue biopsy, non-invasive and real-time monitoring, clinical evidence, and rapid technological advancements. Liquid biopsy allows for the identification of specific biomarkers and genetic mutations associated with each patient's tumor, enabling clinicians to tailor treatment plans based on their unique molecular profile. It also enhances the accuracy of therapy selection, particularly in cases where tissue biopsy results are inconclusive or unavailable. The increasing body of clinical evidence supporting liquid biopsy for therapy selection in lung cancer and rapid technological advancements like next-generation sequencing and digital PCR further contribute to its growth.

Regional Outlook

The global lung cancer liquid biopsy market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Holds Major Market Share

Among all the regions, North America holds a significant share owing to the presence of advanced healthcare infrastructure, strong research and development ecosystem, regulatory framework, early clinical adoption, large patient population, high disease burden, access to capital, and global leadership in biotechnology and healthcare innovation. The US and Canada have well-established regulatory frameworks for medical devices and diagnostic tests, ensuring the safety, efficacy, and quality of liquid biopsy assays. The region's culture of early adoption of medical technologies, high healthcare spending, patient demand for advanced diagnostics, and supportive reimbursement environments drive clinicians to incorporate liquid biopsy into standard cancer care protocols.

The major companies serving the global lung cancer liquid biopsy market include Eurofins Scientific, MDxHealth, CareDx, Immucor, Thermo Fisher Scientific Inc., Menarini Silicon Biosystems, Qiagen, Guardant Health, Exact Sciences Corporation, among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For Instance, in July 2023, Menarini Silicon Biosystems launched its new CellSearch CTC test with the biomarker- DLL3 for the treatment of small-cell lung cancer. This launch helped the organization to expand its development of liquid biopsy assays.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Industry Trends
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. CareDx, Inc.
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Eurofins Scientific SE
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Qiagen NV
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Lung Cancer Liquid Biopsy Treatment Market by Biomarker
  • 4.1.1. Circulating Nucleic Acids
  • 4.1.2. CTC
  • 4.1.3. Exosomes/Microvesicles
  • 4.1.4. Circulating Proteins
• 4.2. Global Lung Cancer Liquid Biopsy Treatment Market by Application
  • 4.2.1. Therapy Selection
  • 4.2.2. Treatment Monitoring
  • 4.2.3. Early Cancer Screening
  • 4.2.4. Recurrence Monitoring
• 4.3. Global Lung Cancer Liquid Biopsy Treatment Market by End-User
  • 4.3.1. Hospitals and Laboratories
  • 4.3.2. Specialty Clinics
  • 4.3.3. Academic and Research Centers
• 4.4. Global Lung Cancer Liquid Biopsy Treatment Market by Product
  • 4.4.1. Instruments
  • 4.4.2. Consumables Kits and Reagents
  • 4.4.3. Software and Services

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World
  • 5.4.1. Latin America
  • 5.4.2. Middle East & Africa

6. Company Profiles

• 6.1. Agilent Technologies, Inc.
• 6.2. Bio-Rad Laboratories, Inc.
• 6.3. Exact Sciences Corp.
• 6.4. Guardant Health
• 6.5. Immucor
• 6.6. LungLife AI, Inc.
• 6.7. MDxHealth
• 6.8. Menarini Silicon Biosystems
• 6.9. Myriad Genetics, Inc.
• 6.10. Thermo Fisher Scientific Inc.